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In the past few years, novel accomplishments have been obtained in carotid baroreﬂex activation therapy (BAT) for the treatment
of resistant hypertension. In addition, this ﬁeld is still evolving with promising results in the reduction of blood pressure and heart
rate.ThisoverviewaddressesthelatestdevelopmentsinBATforthetreatmentofdrug-resistanthypertension.Althoughnottotally
understood considering the working mechanisms of BAT, it appeared to be possible to achieve at least as much eﬃcacy of single-
sided as bilateral stimulation. Therefore unlike the ﬁrst-generation Rheos system, the second-generation Barostim neo operates
by unilateral baroreﬂex activation, using a completely diﬀerent carotid electrode. Also signiﬁcant improvements in several cardiac
parameters have been shown by BAT in hypertensive patients, which set the basis for further research to evaluate BAT as a therapy
for systolic heart failure. Yet important uncertainties need to be clariﬁed to guarantee beneﬁcial eﬀects; hence not all participants
seem to respond to BAT.
1.Introduction
The urgent need for treatments for drug-resistant hyper-
tension has engendered great interest in the development
of new approaches. Carotid baroreﬂex activation is a rela-
tively novel therapy for drug-resistant hypertension. Several
trials have demonstrated the safety and eﬃcacy of this
method in patients with treatment-resistant hypertension
[1, 2]. In addition, the beneﬁts of baroreﬂex activation
t h e r a p y( B A T )a p p e a rt oe x t e n db e y o n db l o o dp r e s s u r e( B P )
reduction and may be applicable for related cardiovascular
disorders.
Recently, several reviews have been published on the role
of baroreceptors in BP regulation, the history of BAT as
a strategy to correct high BP, and the accomplishments of
the carotid baropacer Rheos system. Therefore, this paper
will focus primarily on the latest human developments
in the ﬁeld of BAT for therapy-resistant hypertension.
Prevailing theories and hypotheses that have led to these
new developments will also be discussed. In addition, we will
evaluate the potential indication of BAT in the treatment of
heart failure.
2. CarotidBaroreceptorsand
Mechanisms of BAT
It is widely known that the baroreceptors are mechanosen-
sory nerve endings situated in the inner adventitia of the
arterial wall of carotid sinus and aortic arch and are mainly
associated with BP regulation [3, 4]. Functional anatomy
and neurophysiology of carotid baroreﬂex system have been
extensively described in several reviews and for further
explanation we refer to cited articles [5–7].
2.1. Electrical Carotid Baroreceptor or Baroreﬂex Activation?
During our literature search we noticed two main denomi-
nations of BAT carotid baroreceptor stimulation and carotid
baroreﬂex stimulation. Do we know what is stimulated by a
baropacer: receptor or ﬁbre?
When a mechanosensory receptor is stretched, depolar-
ization may arise by deformation of ionic pores, change
in chemical compounds inside the cell as a result of
stretching, and a transient rise in the membrane potential
while the membrane is being stretched [8]. Normally, an
increase in arterial BP is sensed by baroreceptors through2 Cardiology Research and Practice
their mechanical deformation during vascular stretch. Evi-
dence suggests that sodium and calcium inﬂux through
mechanosensitive ion channels is responsible for depolariza-
tionofbaroreceptorsduringvesselwalldeformation[9].The
ion channel ASIC2 (least acid sensitive subunit), member
of the DEG/ENaC family, appears to be an important
determinant of the arterial baroreceptor complex [10].
Subsequently, signals from the baroreceptors need to be
transformed into action potentials in order to be transported
to the central nervous system (CNS). This mechanoelectrical
transformation occurs in the spike-initiating zone (SIZ) near
the nerve terminals [8, 11]. When depolarization reaches a
speciﬁc threshold, voltage-dependent sodium and potassium
channels are opened to generate action potentials [9]. These
action potentials are then transported through nerve ﬁbres
to CNS for further processing.
Adaptation and resetting are important and remarkable
characteristics of baroreﬂexes [12, 13]. Baroreceptor activity
is not maintained during sustained mechanical changes. The
activity of baroreceptors increases only initially when the
receptors are stimulated but declines over time (adaptation).
Inaddition,thepressurethresholdofbaroreceptoractivation
is increased after a period of acute BP increase (resetting).
The mechanisms of resetting are not totally clariﬁed yet, but
a number of factors including vascular wall distensibility,
alteration in the coupling between receptors and vascular
wall, and receptor properties have been proposed to play a
role in this process [14, 15].
Although the exact mechanisms of mechanosensation
of the baroreceptor are still not totally clear yet, we think
that the current baropacers probably do not stimulate the
mechanosensor itself, as it is mainly activated by its speciﬁc
stimulus (stretch). However, electrical stimulation theoret-
ically may cause ion channels of all types to change their
conformation. Moreover, there are several known substances
whichareabletomodulatethesensitivityofthebaroreceptor
response (e.g., angiotensin II, aldosterone) [16]. In our
opinion induction of an electrical charge to the carotid sinus
wall by a baropacer is more likely to have an eﬀect in the SIZ,
which is rich in voltage-gated channels, and the nerve ﬁbres.
These areas are more sensitive to electrical charge, which
can result in the generation of action potentials. Another
argument which supports the idea of mechanotransduction
bypass during BAT is the absence of adaptation and resetting
in long-term BAT. The BP decrease in subjects treated with
BAT is sustained, even after years of continuous therapy
with the device [17]. In addition, we observed in a limited
number of patients an increase in BP to pretreatment levels
after cessation of long-term BAT, which is consistent with
existing animal data [18]. In case baroreceptors will indeed
be activated by continuous BAT, they will probably undergo
desensitization and response adaptation and theoretically
reset to the prevailing BP decrease even after turning oﬀ the
device. For these reasons it is more likely to assume that the
SIZ and nerve ﬁbres are activated than the receptor itself
during electrical baropacing. Anyhow, the stated arguments
are all indirect evidence for either baroreﬂex or baroreceptor
activationandrequirefurtherresearch.Therefore,wesuggest
thatthetermbaroreﬂexactivationispreferable,asitindicates
the general mechanism of BAT.
2.2. Working Mechanisms of BAT. Although several studies
provided evidence of persistent BP and heart rate reduction
byBAT,theexactneuralmechanismsunderlyingtheseeﬀects
remain to be determined. Two studies revealed a part of
the working mechanisms of the baropacer. Heusser et al.
reported in a study with 12 patients an acute and sharp
decrease in muscle sympathetic nerve activity (MSNA) when
electric carotid baroreﬂex activation was started [19]. This
observation was associated with a signiﬁcant systolic BP
decrease from 193±9mmHg to 161±10mmHg, which can
beexplainedbyadecreaseinsympatheticvasomotortone.In
anotherstudy,Wustmannetal.analyzedheartratevariability
and heart rate turbulence in 21 patients using 24-hour ECG
before device activation and 3 months after device activa-
tion. This study showed, next to a signiﬁcant BP decrease
from 185±31/109±24mmHg to 154±23/95±16mmHg,
sustained changes in heart rate variability and heart rate
turbulence[20].Despitetheirsmallsamplesize,thesestudies
suggest that BAT induces a decrease in sympathetic activity
and an increase in parasympathetic activity.
The aforementioned studies also indicate the potential
role of baroreceptors in long-term BP regulation. The
baroreceptors have been known for a long time to be mainly
responsible for short-term BP regulation. However, their
function in long-term control of BP has been repeatedly
argued. The main arguments against baroreceptor involve-
ment in long-term BP regulation were the little eﬀect on
the average mean arterial pressure (MAP) after sinoaortic
denervation and baroreceptor resetting towards imposed BP
changes [21–23]. On the other hand, investigators including
Sleight and Thrasher have presented results that favor the
idea of a role for baroreceptors in longer term BP levels
[24, 25]. In addition, long-term results of BAT in treatment-
resistant hypertension are consistent with this idea. Several
human studies (DEBuT-HT and Pivotal Trial) demonstrated
that prolonged activation of the carotid baroreﬂex has the
capability of producing signiﬁcant and sustained reductions
in BP without any trend for adaptation. In a single-center
study, BAT showed a pronounced BP decrease of even
53/30mmHg after 4 years of continuous therapy in subjects
with drug-resistant hypertension [17]. This clearly suggests a
potential role for baroreﬂexes in long-term control of arterial
pressure.
Nevertheless, not all patients implanted with a baropacer
showed a response to BAT. Recent long-term Pivotal data
demonstrated a clinically signiﬁcant response to BAT in 88%
of participants, in which a response was deﬁned as achieve-
ment of goal systolic BP (≤140mmHg or ≤130mmHg
in diabetes or renal disease) or a drop in systolic BP
≥20mmHg from start of therapy [26]. In addition, a great
variability in response has been observed. This may be
attributed to various subject characteristics, for instance,
carotid sinus anatomy, race, weight, comorbidity, accuracy
of surgical implantation, concomitant medication use, and
so forth. Moreover, the contribution of diﬀerent geneticCardiology Research and Practice 3
and metabolic factors in the pathophysiology of (resistant)
hypertension may also play a role in the response to BAT.
Therefore, future studies need to focus on adequate patient
selection for BAT.
3. Novel CarotidBaroreﬂexActivationDevices
Electrical activation of the carotid baroreﬂex in resistant
hypertension is not a new concept. In the past several
investigators reported on carotid baroreﬂex activation in
patients with resistant hypertension and angina pectoris.
For a summary of the history of BAT we refer to the
review of Scheﬀers et al. [27]. Although previous experiences
with carotid baropacing reported a consistent BP drop in
the majority of participants, the use of carotid baroreﬂex
activation remained very restricted to experimental settings.
The main reasons for the therapy not achieving common
clinical usage were the technical and surgical limitations at
that time [28].
CVRx Inc. (Minneapolis, MN, USA) has developed a
novel approach for implantable carotid baroreﬂex activation
systems. The ﬁrst generation Rheos system consists of an
implantable pulse generator (IPG) and two carotid sinus
electrodes, which were bilaterally implanted by a surgical
procedure [29]. Device description and implantation proce-
dure have been explained in detail by Tordoir et al. [30].
The second-generation device (Barostim neo)h a s
recently become available. It has received CE marking for
use in resistant hypertension and continues to be studied
in clinical trials. As detailed in Figure 1, the newest device
consists of an IPG and only one carotid sinus electrode
when compared to Rheos system. The IPG in Barostim
neo provides extended battery longevity in a smaller size
(see Figure 2). Furthermore, the programming system is by
wireless telemetry to simplify connection to the device and
modulation of electrical settings. As evident from Figure 3
thenewelectrodeissubstantiallyreducedinsizeandrequires
less power to provide the same beneﬁt. The electrode is
placed unilaterally, typically on the right carotid sinus via a
small skin incision (2.5–5cm). In case of a contraindication
for right-sided implantation (signiﬁcant carotid atheroscle-
rosis, carotid bifurcation above the level of mandible), the
electrode will be placed on the left carotid sinus. Generally,
Barostim neo system is intended to deliver the same eﬀects
for hypertension treatment but reduces risks and duration of
the surgical implantation and hospitalization.
4.Rheos SystemHumanStudies
4.1. BRASS and DEBuT-HT. In 2003 the Baroreﬂex Acti-
vation System Study (BRASS), the ﬁrst human proof-
of-principle trial with the Rheos system, was performed.
Acute voltage-dependent BP drop was observed in 11 nor-
motensive patients undergoing an elective endarterectomy,
which averaged 18mmHg for systolic BP and 8mmHg for
diastolic BP [31]. This served as the basis for the phase
II, multicenter, nonrandomized Device-Based Therapy of
Figure 1: Barostim neo system consisting of an implantable pulse
generator and a unilateral electrode. Programming is performed
by a computer system, which connects to the device by wireless
telemetry. Figure permission was granted by CVRx, Inc.
Figure 2: The implantable pulse generators of the Rheos system
(on the left) and Barostim neo(on the right). Figure permission was
granted by CVRx, Inc.
Hypertension Trial (DEBuT-HT) in 45 patients with drug-
resistant hypertension. The participants showed a mean BP
reduction of 33/22mmHg after 2 years of follow-up [1]. The
safety proﬁle was acceptable, with in total 8 subjects who
experienced a procedure- or device-related serious adverse
event (SAE) [1].
4.2. Pivotal Trial. The Rheos Pivotal Trial was a randomized,
double-blind, phase III trial. It was designed to assess the
safety and eﬃcacy of Rheos system [2]. Patients enrolled
in this study were all experiencing resistant hypertension
despite optimal and adherent antihypertensive therapy. A
total of 265 patients in 49 centres were randomized in a
2:1 fashion and implanted with Rheos system. Group A
consisted of patients who received BAT one month after
implantation of the device (immediate BAT). Group B
started BAT after month 6 of randomization (deferred BAT).
In the primary eﬃcacy endpoint Group A was compared
to Group B for the proportion of subjects that achieved
at least a 10mmHg drop after 6 months of follow-up.
The analysis showed 54% responders in Group A and 46%
responders in Group B (P = 0.97 with 20% superiority
margin). Furthermore, 88% of the responders in Group A
maintained their response after 12 months of BAT. Mean
decrease in systolic BP after 6 months was 16±29mmHg
for Group A and 9±29mmHg for Group B (P =
0.08). The proportion of subjects that achieved a systolic4 Cardiology Research and Practice
Figure 3: The carotid sinus electrodes of Rheos system (on the
right)andBarostimneo(ontheleft).Figurepermissionwasgranted
by CVRx, Inc.
BP ≤140mmHg at 6 months was signiﬁcantly higher in
G r o u pAt h a ni nG r o u pB( P = 0.005). Both groups achieved
a percentage of over 50% at month 12, at which point Group
B already received BAT for 6 months (P = 0.70) [2].
The safety analyses demonstrated an event-free rate of
74.8% for procedure safety. The most common procedure-
related events were transient or permanent nerve injury. BAT
as a therapy showed to be safe with 40% reduction in rate of
hypertensive events in Group A. The device safety yielded an
event-free rate of 87.2% after 12 months [2].
Although the trial did not meet all the prespeciﬁed
endpoints, the overall weight of the provided evidence
suggests that BAT can safely reduce BP over the long term.
Recently published data showed signiﬁcant BP reduction in
long-term BAT [26]. Figure 4 illustrates a systolic BP drop of
>30mmHgbymonth12comparedtopreimplantsystolicBP
intheparticipantsofRheosPivotalTrial.Nonethelessfurther
studies are necessary to provide more insight in the beneﬁts
of BAT.
5.Toward UnilateralBaropacing
The Rheos system provides the ability to optimize and
individualizetheprogrammingofthedeviceforeachpatient.
Although the electrodes of Rheos system were implanted
bilaterally, the majority of participants were programmed
unilaterally in the end [32]. Out of the 322 patients (includ-
ing roll-in patients) enrolled in the pivotal trial 77% had a
unilateral stimulation. Subjects with unilateral BAT showed
as y s t o l i cB Pr e d u c t i o no f3 2±3mmHg and 31±4mmHg
for right- and left-sided programming, respectively, after 6
months of BAT. This was comparable to patients who had
bilateral BAT (21±4mmHg decrease in BP). These results
suggest that it is not necessary to activate both left and right
carotid baroreﬂex pathways to achieve maximum decrease
in BPs. However, these data do not clearly suggest if there
is a preferred side on which carotid sinus side should be
stimulated.
Previous attempts to evaluate the individual eﬀect of
single left- or right-sided carotid baroreceptor activation
did also not deliver conclusive results in humans. The
idea of functional asymmetry and side dominance in the
function of the carotid baroreﬂexes seems plausible. This
may be due to right/left diﬀerences in cardiac innervation
and projections of baroreceptor aﬀerents to CNS [33].
Williamson et al. found left-sided dominance for MSNA
by direct measurements from right peroneal nerve during
unilateral sustained neck pressure by a neck collar device
in 10 healthy volunteers [34]. In contrast, Furlan et al.
showed no functional asymmetry in sympathetic discharge
in response to unilateral neck suction in 12 healthy subjects
[35]. Regarding the carotid-cardiac baroreﬂexes Williamson
and Raven suggested that right and left cardiac reﬂexes are
quantitatively similar [36], while right-sided baroreceptor
activation was found more eﬀective in modulating R-R
interval by Taﬁl-Klawe et al. and Furlan et al. [33, 35].
Although animal data reported greater eﬀects on heart rate
with right-sided activation [37], comparisons of bilateral
and unilateral baroreceptor activation and their eﬀect on
heart interval and peripheral resistance in humans provided
conﬂicting ﬁndings [35, 36].
The development of the unilateral baropacers is certainly
supported by the present Pivotal data. However, previous
research did not provide enough basis to favor a speciﬁc
carotid sinus side over the other. Therefore, further work is
needed to determine what carotid sinus side should ideally
beactivatedandtowhatamountinterindividualvariabilityis
present in side dominance. Studies conducted with Barostim
neo will probably add knowledge to the physiologic diﬀer-
ences of unilateral carotid baroreﬂex function, as patients
who lack adequate BP response to right-sided BAT have
the opportunity to get an additional carotid sinus electrode
implanted on the left side.
6.Barostim neo Human Studies
6.1. XR-1 Veriﬁcation Study. T h eﬁ r s th u m a nt r i a lw i t ht h e
secondgenerationofcarotidbaroreﬂexactivatorsis theXR-1
Veriﬁcation Study, which is currently in progress. The
purposeistoassessthesafetyandeﬃcacyoftheBarostimneo
system in patients with drug-resistant hypertension. Forty
subjectsareincludedinthisnonrandomized, open-labeltrial
at up to 15 clinical sites in Europe and Canada. All partic-
ipants will be implanted with Barostim neo and therapy is
started 2 weeks after implantation of the device. Preliminary
datareportedbyHasenfussetal.[38]attheEuropeanSociety
of Cardiology meeting (ESC 2011) showed that systolic BP
decreased by 28.7mmHg in 12 patients after 3 months of
continuous unilateral right-sided BAT. This is comparable to
results obtained by the Rheos system. The safety proﬁle of
Barostim neo in 32 participants was substantially improved
when compared to the ﬁrst generation device. In the 30-day
postprocedural safety only 3 complications occurred (pocket
hematoma, self-inﬂicted wound complication, and device
repositioning due to IPG discomfort). One system-related
complication was reported, consisting of pain near the IPG.
Final results of this study are still pending, but it seems
that the new conﬁgurations of the second-generation device
improved the safety proﬁle of BAT [39].Cardiology Research and Practice 5
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Figure 4: Systolic blood pressure values from screening, randomized phase, and long-term follow-up of subjects participating in Pivotal
Trial. SBP:systolic blood pressure; BPTru:blood pressure measuring device; SE:standard error (Used from Bakris et al. [26]).
7.BATinHeart Failure
The mechanism of action of baroreceptors may make BAT a
therapeutic tool for a wide range of cardiovascular diseases
including heart failure. Beneﬁcial eﬀects of BAT on cardiac
parameters have been observed in resistant-hypertensive
patients treated with Rheos system. Data from the DEBuT-
HT reported improvements in functional capacity. Kroon
et al. [40] found an increase in 6-minute hall walk after
12 months of BAT. Improvements in cardiac structure were
also observed by echocardiographic analyses [40, 41]. In
a substudy of DEBuT-HT, Bisognano et al. presented a
signiﬁcant left ventricular mass index (LVMI) decrease from
138.9±6.0 to 114.3±3.9g/m2 and a signiﬁcant increase
in median Left Ventricular Ejection Fraction (LVEF) from
65% to 67% after 12 months of continuous therapy [42].
Furthermore, BAT reduced left atrial dimension, left ven-
tricular wall thickness, and mitral A-wave velocity. Cardiac
data from pivotal trial also showed positive results in a
substudy which included 46 patients. LVMI decreased from
117.7±4.3 to 99.9±3.0g/m2.7 one year after activation
[43]. Left ventricular mass decreased from 260.2±11.9
to 222.9±6.9g in the same time period. These changes
probablycontributetotheimprovementindiastolicfunction
and provide an attractive strategy for the treatment of heart
failure with preserved ejection fraction (HFpEF). A recent
paper of Georgakopoulos et al. presents a clear overview of
evidence suggesting BAT as a potential therapy for HFpEF
[44].
Although current data demonstrated the eﬀects of BAT
only in hypertensive patients with various degrees of HFpEF,
BAT may also be beneﬁcial in patients with reduced EF
(HFrEF) as these two share pathophysiologically much in
common. A feasibility study is already ongoing to assess
the potential beneﬁt of Barostim neo BAT in patients with
advanced heart failure. Main inclusion criteria are age
between 21 and 80 years and symptomatic heart failure
despite optimal, stable medical therapy for at least 4 weeks.
Furthermore, a phase III XR-1-randomized heart failure
study in patients with ischemic cardiomyopathy and reduced6 Cardiology Research and Practice
LVEF is going to start in the near future. Up to 300 subjects
will be enrolled at about 30 clinical centres in Europe and
Canada. Participants will be randomized in a 1:1 fashion
to receive BAT on top of standard medical therapy or to
receive optimal medical therapy alone. The primary eﬃcacy
endpoint will be to determine the change in left ventricular
ejection fraction in subjects who receive BAT compared to
standard medical care after 6 months of follow-up.
8. Conclusions andFuturePerspectives
The great necessity to alternative and eﬀective BP reducing
strategies created movement towards device-based therapies.
BAT showed to be safe and eﬀective for the treatment
of drug-resistant hypertension. In addition, this approach
seems to have potential in patients with heart failure and fur-
ther eﬀorts are being undertaken to evaluate the applicability
in other cardiovascular diseases. However, various key issues
remaintobeidentiﬁedintheﬁeldofcarotidbaropacing.The
device is still undergoing progressive technical development
to improve safety and increase the beneﬁt and comfort
for the user. Furthermore, uncertainties about the exact
working mechanism and selection of optimal candidates for
this therapy need to be explored. Future studies on BAT
need to provide insight into appropriate patient selection
and best device settings (unilateral versus bilateral activation
and side-dominance) and expand the knowledge about the
(patho) physiology and function of carotid baroreceptors in
BP regulation.
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